FlightPath Biosciences
Birmingham, US · Founded 2019 · Delaware corporation
Founders & leadership
MT
Matthew TindallExecutive
MP
Mark P. de SouzaNamed on SEC filing
Board
CS
Curtis ScribnerBoard director
CL
Cristina LarkinBoard director
Reported raises · per SEC filings
Form D private placements$9.6M disclosed across 2 rounds · 2020–2023
▶$8.1MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$8.1MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis ScribnerDirector
- Matthew TindallExecutive Officer, Director
- Cristina LarkinDirector
- Offering amount
- $9M
- Amount sold
- $8.1M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedDec 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedDec 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark P. de SouzaExecutive Officer, Director
- Curtis L. ScribnerExecutive Officer
- Matthew Charles TindallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has FlightPath Biosciences raised?
- FlightPath Biosciences has disclosed $9.6M raised across 2 rounds.
- Where is FlightPath Biosciences headquartered?
- FlightPath Biosciences is headquartered in Birmingham, US.